Phase 3 ASTRAL-2 and ASTRAL-3 studies of guadecitabine in patients with previously treated acute myeloid leukaemia and myelodysplastic syndromes fail to meet primary endpoint

Neither study of this next-generation DNA hypomethylating agent met the primary endpoint of statistically significant (p <0.05) improvement in overall survival compared with the control arm of physicians’ choice of alternative therapy.

Biospace Inc.